3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
pembrolizumab
16
Radiotherapy
15
Drug Therapy
14
Paclitaxel
13
Cisplatin
12
Carboplatin
10
Immunotherapy
9
Esophagectomy
9
Radiation
8
Fluorouracil
8
Surgical Procedures, Operative
7
Capecitabine
7
Blood Specimen Collection
7
Oxaliplatin
6
Nivolumab
6
Immune Checkpoint Inhibitors
6
Chemoradiotherapy
6
nimotuzumab
5
Trastuzumab
5
130-nm albumin-bound paclitaxel
5
sintilimab
4
camrelizumab
4
Leucovorin
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Surveys and Questionnaires
3
Endoscopy
3
Bevacizumab
3
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Neoplasms
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled